ライフサイエンスコーパス: connective tissue disease

1 limited specificity for a single autoimmune connective tissue disease.

2 try), and had not developed IcSSc or another connective tissue disease.

3 but often fatal, occurrence in patients with connective tissue disease.

4 thematosus and in patients who have no known connective tissue disease.

5 tibodies is associated with undifferentiated connective tissue disease.

6 d related vasculitides even in patients with connective tissue disease.

7 for vasculitis was 99.5% among patients with connective tissue disease.

8 tests are obtained to screen for an emerging connective tissue disease.

9 gnificantly increased in patients with mixed connective tissue disease.

10 dication at onset, 6 had cancer, and 3 had a connective tissue disease.

11 ssociated with statin medication, cancer, or connective tissue disease.

12 unities and were screened for the absence of connective tissue disease.

13 of prolyl 3-hydroxylation is a mechanism for connective tissue disease.

14 entified 586 new instances of vasculitis and connective tissue disease.

15 with neurodegeneration and/or cataracts and connective tissue disease.

16 ractions and mechanisms of joint disease and connective tissue disease.

17 recessive inheritance of TNX deficiency and connective-tissue disease.

18 ic sclerosis, but not in patients with other connective tissue diseases.

19 es that will help to explain the etiology of connective tissue diseases.

20 n scarring, fibrosis, poor wound healing and connective tissue diseases.

21 to study autoimmunity in a wider spectrum of connective tissue diseases.

22 us system manifestations of vasculitides and connective tissue diseases.

23 RNP is a prominent target of autoimmunity in connective tissue diseases.

24 shed light on the misfolding of collagen in connective tissue diseases.

25 Self-reported connective-tissue diseases.

26 uld not be likely to reduce the incidence of connective-tissue diseases.

27 immunodeficiency virus (HIV) infection (45), connective-tissue disease (39), substance abuse (37), th

28 FDG score: 3.27+/-1.22), and 2 patients with connective tissue disease (5.07 and 7.11) compared with

29 was 49+/-14 years, 78% were female, 33% had connective tissue disease, 52% were in New York Heart As

30 ciation between silicone breast implants and connective tissue diseases, a conclusion recently endors

31 es that add to the growing list of monogenic connective tissue disease affecting the arterial wall, a

32 ants specifically, and any of the individual connective-tissue diseases, all definite connective-tiss

33 tyly, and telangiectasias syndrome and mixed connective tissue disease also had significantly higher

34 e risk (RR) of the combined end point of any connective-tissue disease among those who reported breas

35 ard, but do suggest small increased risks of connective-tissue diseases among women with breast impla

36 ase can occur in association with autoimmune connective tissue disease and confound the clinical pict

37 resent a case report of a patient with mixed connective tissue disease and non-insulin-dependent diab

38 nus is not associated with increased risk of connective tissue disease and that most patients in the

39 Compared with 5,457 patients with connective tissue diseases and pneumonia due to other or

40 ighest for neoplasms and musculoskeletal and connective tissue diseases and was most accurate for sch

41 CAD patients, whereas peptic ulcer disease, connective tissue disease, and lymphoma were less signif

42 f P carinii pneumonia (PCP) in patients with connective tissue diseases, and to determine the role th

43 n; and patients with PAH in association with connective tissue disease are identified as a particular

44 Patients with connective tissue disease are known to develop multiple

45 Hereditary connective tissue diseases are associated with mutations

46 Genes important in the connective tissue diseases are being recognized in two b

47 Autoimmune connective tissue diseases are clinically variable, maki

48 Bruck Syndrome is a connective tissue disease associated with inactivating m

49 These mutants may be useful in treating connective tissue diseases associated with increased met

50 To characterize the T cell response to a connective tissue disease-associated autoantigen, this s

51 are how best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD)--diso

52 valent in patients with SSc-PAH (n = 81) and connective tissue disease-associated PAH (n = 110) compa

53 patients with schistosomiasis-associated and connective tissue disease-associated PAH had evidence of

54 patients with schistosomiasis-associated and connective tissue disease-associated PAH was also system

55 levels in men with idiopathic, heritable, or connective tissue disease-associated PAH were compared w

56 ously been a case of PCP in a patient with a connective tissue disease at the same hospital (OR 135,

57 n 1976, and were free from SLE and any other connective tissue disease at the time of enrollment.

58 reported breast implants and 11,805 reported connective-tissue diseases between 1962 and 1991.

59 Calcinosis cutis is common in several connective tissue diseases but rare in systemic lupus er

60 been increasingly reported in patients with connective tissue diseases, but the frequency of this co

61 ell clones were generated from patients with connective tissue disease by using either a recombinant

62 It is often accompanied by statin therapy, connective tissue diseases, cancer, and autoantibodies s

63 Osteogenesis imperfecta (OI) is a heritable connective tissue disease characterized by bone fragilit

64 mportant role in systemic sclerosis (SSc), a connective tissue disease characterized by inflammation,

65 or scleroderma (SSc) is a complex autoimmune connective tissue disease characterized by obliterative

66 icans progressiva (FOP) is a rare hereditary connective tissue disease characterized by progressive p

67 (SSc), also known as scleroderma, is a rare connective tissue disease characterized by vascular and

68 dence interval, 0.65 to 3.11]); all definite connective-tissue diseases combined (0.80; 95 percent co

69 ual connective-tissue diseases, all definite connective-tissue diseases combined, or other autoimmune

70 All had connective tissue disease (CTD) serologies, spirometry,

71 To compare self-report of connective tissue disease (CTD) with medical records, su

72 al solvent exposure may increase the risk of connective tissue disease (CTD).

73 etermine whether anti-Gu antibodies occur in connective tissue diseases (CTD) and, if so, to determin

74 Inflammatory connective tissue diseases (CTD) like lupus and rheumato

75 plication to SV, in both primary disease and connective tissue diseases (CTD), is reviewed here.

76 Patients with connective tissue diseases (CTD), who may be predisposed

77 id arthritis (RA), and 25 (0.26%) with other connective tissue diseases (CTDs).

78 ly identified as an autoantigen in the human connective tissue disease dermatomyositis [14,15].

79 inimal effect on the number of women in whom connective-tissue diseases develop, and the elimination

80 creased risk: previous high-dose procedures, connective tissue disease, diabetes mellitus, and homozy

81 inosis is a recognized manifestation of many connective-tissue diseases, especially juvenile dermatom

82 c studies has been to exclude large risks of connective-tissue diseases following breast implants.

83 le localized scleroderma stand out among the connective tissue diseases for their multiorgan involvem

84 Connective tissue diseases frequently appear in the diff

85 Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean ri

86 T cell dependence of autoimmune responses in connective tissue diseases has been well established, li

87 Animal models of systemic connective tissue diseases have provided valuable insigh

88 using multivariable Cox regression analysis: connective tissue disease (hazard ratio [HR] 2.94, 95% c

89 complication of systemic conditions, such as connective tissue disease, HIV infection, or chronic liv

90 ics between these patients and patients with connective tissue diseases hospitalized with other types

91 ical forms of inflammatory syndromes such as connective tissue diseases, human immunodeficiency virus

92 natural history of RP not associated with a connective tissue disease in a large, community-based po

93 Scleroderma is an autoimmune connective tissue disease in which patients make antibod

94 Systemic sclerosis is an autoimmune connective tissue disease in which T cells play a promin

95 familial Mediterranean Fever, and the rarer connective tissue diseases, in particular systemic lupus

96 e individual diseases, the finding for other connective-tissue diseases (including mixed) was statist

97 ta demonstrate that RP not associated with a connective tissue disease is frequently a transient phen

98 In addition, some children in whom mixed connective tissue disease is initially diagnosed ultimat

99 ne gel in relation to idiopathic or atypical connective tissue disease is not clear.

100 e true prevalence of PAH among patients with connective tissue disease is unknown.

101 lmonary fibrosis occurring in the context of connective tissue diseases is often characterized by a d

102 Scleroderma, a debilitating acquired connective tissue disease, is characterized by fibrosis,

103 s erythematosus, systemic scleroderma, mixed connective tissue disease, juvenile dermatomyositis, juv

104 Recent studies also indicate a possible connective tissue disease-like syndrome with parvoviral

105 t an association between breast implants and connective tissue disease-like syndromes.

106 from controls or patients with other non-SSc connective tissue diseases (lupus, rheumatoid arthritis,

107 roderma (SSc) is a complex and heterogeneous connective tissue disease mainly characterized by autoim

108 protein fibrillin-1, result in the dominant connective tissue disease Marfan syndrome.

109 Mixed connective tissue disease (MCTD) is a systemic autoimmun

110 A defining feature of mixed connective tissue disease (MCTD) is the presence of anti

111 eroderma (systemic sclerosis [SSc]) or mixed connective tissue disease (MCTD).

112 erythematosus (SLE) and 1 patient with mixed connective tissue disease (MCTD).

113 pe relationship for several classes of human connective tissue diseases, mechanisms of integrin clust

114 itis, spondyloarthritis, DILS, vasculitides, connective tissue disease, myopathies, and musculoskelet

115 M) (n=102), myositis associated with another connective tissue disease (myositis-CTD overlap syndrome

116 Raynaud phenomenon without previously known connective tissue disease, nailfold capillaroscopy and l

117 Systemic sclerosis (SSc) is an autoimmune connective tissue disease of unknown etiology in which T

118 has indicated that the rate of well-defined connective tissue disease or breast cancer has greatly i

119 PAH patients (idiopathic, or associated with connective tissue disease or congenital heart disease) w

120 hypertension that was idiopathic, related to connective tissue disease or congenital heart disease, w

121 arditis/perimyocarditis; 85% idiopathic, 11% connective tissue disease or inflammatory bowel disease,

122 ut bias due to differential overreporting of connective-tissue diseases or selective participation by

123 esents a single disease entity, namely mixed connective tissue disease, or an undifferentiated autoim

124 R and -ETAR Abs are more frequent in SSc-PAH/connective tissue disease-PAH compared with other forms

125 ucleic acid (NA) binding Ab occur in vivo in connective tissue disease patients and certain inbred st

126 ere used to screen sera from 554 consecutive connective tissue disease patients.

127 These illnesses include connective tissue diseases, portal hypertension, diet an

128 include the use of beta-blocking agents, and connective tissue disease processes such as systemic lup

129 iagnosis of idiopathic pulmonary fibrosis or connective tissue disease-related interstitial lung dise

130 od for IPF (kappaw=0.71 [IQR 0.64-0.77]) and connective tissue disease-related interstitial lung dise

131 summary adjusted relative risk of individual connective-tissue diseases (rheumatoid arthritis, 1.04 [

132 76 and 2002) in 674 women was confirmed by a connective tissue disease screening questionnaire and bl

133 80 and 2000) was confirmed in 480 women by a connective tissue disease screening questionnaire and me

134 nd point, definite RA, was confirmed using a connective tissue disease screening questionnaire, follo

135 anti-SSA/Ro-positive sera from patients with connective tissue diseases showed high reactivity to the

136 opathic, associated with congenital heart or connective tissue disease) started bosentan with or with

137 r contracture and calcification and possibly connective tissue diseases such as scleroderma and rheum

138 se subunits are autoantigens associated with connective tissue diseases such as systemic lupus erythe

139 n and consequently cause the pathogenesis of connective tissue diseases such as tendinopathy and oste

140 Studies of scleroderma and other defined connective tissue diseases suggest that implant recipien

141 s, or scleroderma, is an uncommon autoimmune connective tissue disease that results in systemic fibro

142 estimated the annual number of new cases of connective-tissue disease that could be attributed to br

143 al blood cells from patients with autoimmune connective tissue diseases, the cell type-specific analy

144 ial hypertension (primary or associated with connective-tissue disease) to receive placebo or to rece

145 era from patients with scleroderma and mixed connective tissue disease, two systemic fibrotic disease

146 tigate the relation between undifferentiated connective tissue disease (UCTD) and solvent exposure in

147 hio who were diagnosed with undifferentiated connective tissue disease (UCTD) to investigate the sign

148 A connective tissue disease was diagnosed in 30% and B-cel

149 Two hundred twenty-three patients with connective tissue diseases were diagnosed with PCP in th

150 this condition is diagnosed in patients with connective tissue diseases who present with pneumonia, s

151 ittle cornea syndrome (BCS2) is an inherited connective tissue disease with a devastating ocular phen

152 c sclerosis (SSc; scleroderma) is a systemic connective tissue disease with an extensive vascular com

153 i-SSA/Ro Ab-positive sera from patients with connective tissue diseases with the E-pore peptide opens

154 recently published data about calcinosis in connective-tissue diseases with emphasis on the pathogen

155 t multiple genes are involved in each of the connective tissue diseases, with some genes in common th

156 ents with PAH, idiopathic or associated with connective tissue disease, World Health Organization (WH